Somewhat Positive News Coverage Somewhat Unlikely to Affect Abbott Laboratories (ABT) Stock Price

Press coverage about Abbott Laboratories (NYSE:ABT) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Abbott Laboratories earned a daily sentiment score of 0.07 on Accern’s scale. Accern also gave news stories about the healthcare product maker an impact score of 47.5769254230639 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:

Several equities analysts have recently weighed in on ABT shares. ValuEngine lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Stifel Nicolaus upped their price objective on shares of Abbott Laboratories from $58.00 to $63.00 and gave the company a “buy” rating in a report on Thursday, October 19th. BMO Capital Markets reiterated a “hold” rating and set a $53.00 price objective on shares of Abbott Laboratories in a report on Friday, September 1st. Zacks Investment Research upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $61.00 price objective on the stock in a report on Tuesday, October 31st. Finally, Cowen reiterated a “buy” rating and set a $55.00 price objective on shares of Abbott Laboratories in a report on Thursday, August 17th. Eight analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Abbott Laboratories currently has a consensus rating of “Buy” and a consensus target price of $56.81.

Abbott Laboratories (NYSE:ABT) traded down $0.05 on Friday, hitting $54.64. 5,100,000 shares of the company were exchanged, compared to its average volume of 5,400,000. The company has a quick ratio of 2.26, a current ratio of 2.69 and a debt-to-equity ratio of 0.72. Abbott Laboratories has a 12 month low of $37.90 and a 12 month high of $56.69. The firm has a market cap of $95,110.00, a price-to-earnings ratio of 22.67, a PEG ratio of 2.05 and a beta of 1.55.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.01. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. The company had revenue of $6.83 billion for the quarter, compared to analyst estimates of $6.72 billion. During the same quarter in the prior year, the business posted $0.59 EPS. The firm’s revenue was up 28.8% compared to the same quarter last year. sell-side analysts predict that Abbott Laboratories will post 2.49 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th were paid a $0.265 dividend. The ex-dividend date of this dividend was Thursday, October 12th. This represents a $1.06 annualized dividend and a yield of 1.94%. Abbott Laboratories’s dividend payout ratio (DPR) is 87.60%.

In other Abbott Laboratories news, insider Jaime Contreras sold 52,700 shares of the stock in a transaction dated Friday, September 22nd. The shares were sold at an average price of $51.97, for a total value of $2,738,819.00. Following the completion of the sale, the insider now owns 58,739 shares in the company, valued at approximately $3,052,665.83. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Chairman Miles D. White sold 276,886 shares of the stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $54.41, for a total transaction of $15,065,367.26. Following the completion of the sale, the chairman now owns 3,677,913 shares of the company’s stock, valued at approximately $200,115,246.33. The disclosure for this sale can be found here. In the last quarter, insiders sold 588,013 shares of company stock valued at $32,023,946. Company insiders own 0.76% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Abbott Laboratories (ABT) Stock Price” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2017/12/10/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-abbott-laboratories-abt-stock-price.html.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Insider Buying and Selling by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply